Abstract:Background: Cancer stem cells (CSCs) are a rare population of tumor initiating cells associated with chemoresistance, recurrence and poor survival. Our group previously correlated germline variants in ovarian CSC-related genes with chemoresponse in 362 high-grade serous ovarian cancer (HGSOC) patients. Here, we evaluate CSC variants in a large, independent population to determine their association with overall (OS) and progression-free (PFS) survival.Methods: Over 2,500 women of European ancestry diagnosed with HGSOC who underwent cytoreductive surgery have been followed for clinical outcome and genotyped on the OncoArray. We identified 4,209 common (MAF>0.01) short polymorphisms (SNPs) that were genotyped or well-imputed (r2>0.70) within 26 CSC-related genes. Associations with OS and PFS were estimated with additive genetic cox proportional hazards models adjusted for ancestral principal components, age at diagnosis, and study. Residual disease after surgery (≤1cm vs. >1cm), and stage at diagnosis (advanced vs. local) were assessed for confounding (covariate), modification (interaction), and mediational (logistic regression) effects. For each SNP, the best fit model was adopted and p-values were adjusted for multiple testing using a false discovery rate (FDR) < 15% threshold. Primary analyses evaluated 1,254 patients who received standard chemotherapy; secondary analysis included 2,659 patients, regardless of chemotherapy regimen.Results: Two genes that were previously associated with response to chemotherapy (ESRRB, ALDH1A1) and two new genes (NOTCH2, CXCR4) were associated with OS and PFS. Eight variants within ESRRB were significantly associated with improved OS and comprised four independent (rsq<0.2) intronic variants. The top hit rs7160216 (HR=0.61, P=8.4x10-7, FDR=0.004) was modified by residual disease with the association attenuated in optimally debulked patients (HR=0.88, P interaction=0.05). One independent variant in ALDH1A1 was associated with an almost 2-fold lower OS (rs17563633 HR=1.80, P=7.2x10-5, FDR=0.03) and a ~6-fold lower OS in suboptimally debulked patients (HR=5.8, P interaction=9.2x10-4). Analysis of all patients, irrespective of chemotherapy, identified a significant association for rs17848385 in CXCR4 with reduced OS (HR=1.36, P=1.3x10-5, FDR=0.05). Aforementioned variants also displayed similar, significant associations with PFS though without modification. No significant SNP effects on survival were mediated through residual disease or stage; however, uncorrelated SNP blocks in ESRRB and ALDH1A1 associated with these factors proposing possible genomic interaction.Conclusion: Polymorphisms in CSC genes are associated with survival of HGSOC and more research is needed to clarify the prognostic value of these genes, particularly as carriers may benefit from emerging therapies targeting CSC pathways.Citation Format: Brett M. Reid, Jennifer B. Permuth, Zhihua Chen, Ann Chen, Thomas A. Sellers, on behalf of the Ovarian Cancer Association Consortium (OCAC). Germline polymorphisms in cancer stem cell genes associate with survival among women with high-grade serous ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1562.

Association of BRCA 1 and BRCA 2 Mutations with Survival , Chemotherapy Sensitivity , and Gene Mutator Phenotype in Patients with Ovarian Cancer

Association of somatic mutations in BRCA2 BRC domain with chemotherapy sensitivity and survival in high grade serous ovarian cancer

Association of somatic mutations in <i>BRCA2</i> BRC domain with chemotherapy sensitivity and survival in high grade serous ovarian cancer

BRCA mutations in the manifestation and treatment of ovarian cancer.

Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations

Somatic Mutations in BRCA2 BRC Repeat Associated with Outcome in Patients with High Grade Serous Ovarian Cancer

Abstract LB-255: Exome Mutation Burden Predicts Clinical Outcome in Ovarian Cancer Carrying Mutated BRCA1 and BRCA2 Genes.

Abstract 1562: Germline Polymorphisms in Cancer Stem Cell Genes Associate with Survival among Women with High-Grade Serous Ovarian Cancer

Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer.

Abstract P3-08-51: Association Between BRCA Mutational Status and Survival in Patients with Breast Cancer: A Meta-Analysis

Comparison of Clinical Outcomes of BRCA1/2 Pathologic Mutation, Variants of Unknown Significance, or Wild Type Epithelial Ovarian Cancer Patients

Effects of BRCA1- and BRCA2-related Mutations on Ovarian and Breast Cancer Survival: a Meta-Analysis.

Germline and Tumor BRCA1/2 Mutations in Chinese High Grade Serous Ovarian Cancer Patients.

XRCC1 polymorphism and overall survival in ovarian cancer patients treated with platinum-based chemotherapy: A systematic review and MOOSE-compliant meta-analysis.

Survival Benefit of Germline BRCA Mutation is Associated with Residual Disease in Ovarian Cancer

Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma

BRCA Mutation Frequency and Clinical Features of Ovarian Cancer Patients: A Report from a Chinese Study Group

Clinical characterization and therapeutic outcomes of patients (pts) with colorectal cancer (CRC) harboring somatic BRCA1/2 mutations.

Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer

BRCA1/2 Mutations and Survival of High-Grade Endometrioid Endometrial Cancer

Association Between BRCA Mutational Status and Survival in Patients with Breast Cancer: a Systematic Review and Meta-Analysis